ADMA Biologics develops, manufactures, and markets specialty plasma-derived biologics for immune deficiencies and infectious diseases. The company offers IVIG products BIVIGAM and ASCENIV, as well as Nabi-HB for Hepatitis B exposure. It also develops a pipeline of plasma-derived therapeutics and operates source plasma collection facilities. Products are sold through independent distributors, wholesalers, pharmacies, and alternate site providers.
| Indicator | Value |
|---|---|
| PER | 33.2 |
| EV/EBITDA | 12.5 |
| Price/Free Cash Flow' | 8.5 |
| ROIC | 17.5% |
| Net Debt/EBITDA | 2.1 |